What the 2026 Cholesterol Guidelines Changed — And What I've Been Doing All Along

He came in with a clean cholesterol panel. Total cholesterol 185, LDL 112, HDL 52. His primary care doctor had reviewed it, told him everything looked great, and sent him on his way.

Nobody had ever ordered an Lp(a).

His father had a heart attack at 49. His brother had a stent placed at 52. He was 44, otherwise healthy, every standard metric in range. When I ran his Lp(a), it came back at 287 nmol/L. That's roughly a 3-fold increased cardiovascular risk compared to someone with a normal level. His LDL was never the story. Lp(a) was.

This is exactly what the 2026 ACC/AHA Guideline on the Management of Dyslipidemia was written to prevent.

In April 2026, the American College of Cardiology and the American Heart Association released a new dyslipidemia guideline that formally replaces the 2018 version. It changes how cardiovascular risk is calculated, which labs should be ordered, and what the treatment targets are. Some of what it says is genuinely new. Some of it, I'll be honest, is what careful clinicians have been doing for years.

Here's what the guideline actually changes, what it means for your care, and where the standard of care has finally caught up.

What Changed from 2018 to 2026

The 2018 guideline focused heavily on LDL cholesterol and percentage-based reduction targets. The 2026 guideline shifts to a broader view: cardiovascular risk is driven by prolonged exposure to all atherogenic lipoproteins, not just LDL. That means triglycerides, remnant particles, and Lp(a) are now formally part of the conversation.

Here's the side-by-side:

Topic	2018	2026
LDL-C Estimation	Friedewald formula preferred	Martin/Hopkins or Sampson/NIH equations preferred
Primary Prevention Risk Tool	Pooled Cohort Equations (PCE)	PREVENT-ASCVD equations (10-year and 30-year)
Risk Threshold for Treatment	Generally ≥ 7.5%	New ≥ 3% threshold to begin considering therapy
Lp(a) Testing	Not routinely recommended	Recommended at least once in all adults (Class I)
Treatment Targets	Percentage reduction emphasis	Absolute LDL-C, Non-HDL-C, and ApoB goals reinstated
ApoB	Not specified for routine use	Recommended in high-risk patients with diabetes, CKM, or elevated TG

Source: 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.

The shift from percentage reduction targets to absolute goals is one I welcome. "Reduce your LDL by 50%" means something very different depending on where you start. An absolute target — LDL under 70 mg/dL, ApoB under 55 mg/dL — removes that ambiguity.

Lp(a): The Risk Factor Most Patients Have Never Heard Of

Lipoprotein(a), or Lp(a), is a genetically determined lipoprotein that carries significant cardiovascular risk independent of LDL. It doesn't respond to statins. It doesn't change meaningfully with diet. You are largely born with your Lp(a) level and it stays there.

The 2026 guideline now gives Lp(a) measurement a Class I recommendation — meaning it should be measured at least once in every adult. This is long overdue.

Here is how the risk scales with Lp(a) level:

Lp(a) (nmol/L)	Lp(a) (mg/dL)	ASCVD Relative Risk Increase
< 75	< 30	Reference
75–124	30–49	1.2-fold
125	50	1.4-fold — Risk Enhancement Threshold
250	100	2-fold
350	150	3-fold
430	180	4-fold

Source: 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.

I have ordered Lp(a) on every new patient since I opened Well Endocrinology. Not because a guideline told me to — because the data has supported it for years and because you cannot manage risk you haven't measured. The guideline caught up. The clinical reasoning didn't change.

When Lp(a) is elevated, the goal shifts: we cannot lower Lp(a) with current approved therapies (though agents like olpasiran are in trials), so we focus on driving LDL and ApoB as low as possible to reduce overall burden. That's a different conversation than "your LDL looks fine”

The New Risk Calculator: PREVENT-ASCVD

The 2026 guideline replaces the old Pooled Cohort Equations with a newer model called PREVENT-ASCVD, which calculates both 10-year and 30-year cardiovascular risk for adults aged 30 to 79.

The 30-year estimate matters more than it might seem. A 35-year-old with borderline cholesterol and a strong family history might have a 10-year risk that looks reassuring. Her 30-year risk tells a different story. That longer view is where prevention decisions should be made.

The guideline also drops the treatment consideration threshold from 7.5% to 3% for 10-year risk. That means more patients will qualify for a conversation about lipid-lowering therapy, not because the threshold moved arbitrarily, but because the accumulated evidence on lifelong LDL exposure makes starting earlier, in the right patients, worth it.

How risk gets calculated and refined:

The guideline uses a three-step framework called CPR: Calculate, Personalize, Reclassify.

1. Calculate: Run the PREVENT-ASCVD equations for 10-year and 30-year risk.

2. Personalize: Adjust for factors the calculator doesn't capture — premature family history, chronic inflammatory disease, early menopause (before age 45), preeclampsia, gestational diabetes, elevated hsCRP, or high-risk ancestry. South Asian descent is named explicitly as a risk-enhancing factor. This matters. South Asian patients often have significant cardiometabolic risk at LDL levels that wouldn't trigger intervention in a standard calculation.

3. Reclassify: If there's clinical uncertainty, use Coronary Artery Calcium (CAC) scoring to guide the decision.

CAC Score	Clinical Implication
CAC = 0	Reasonable to defer therapy (exceptions: smokers, diabetes, severe hypercholesterolemia)
CAC 1–99	Consider moderate-intensity statin (COR 2a)
CAC 100–299 (or ≥ 75th percentile)	Initiate lipid-lowering therapy (COR 1)
CAC 300–999	Target higher-intensity therapy (COR 1)
CAC ≥ 1000	High-intensity therapy; LDL goal < 55 mg/dL (COR 1)

Source: 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.

I use CAC scoring regularly in new patient workups for this reason. A CAC of 0 in a patient with borderline risk is genuinely reassuring and can defer therapy. A CAC of 450 in someone whose calculated risk looked intermediate completely reframes the conversation.

Treatment Targets by Patient Group

The return of absolute lipid goals is one of the more practically useful changes in the 2026 guideline. Here are the targets across patient groups:

Patient Group	LDL-C Goal (mg/dL)	Non-HDL-C Goal (mg/dL)	ApoB Goal (mg/dL)
Primary Prevention (< 10% risk)	< 100	< 130	< 90 (if TG 150–499)
Primary Prevention (≥ 10% risk)	< 70	< 100	< 70 (if TG 150–499)
Diabetes (No major risk factors)	< 100	< 130	< 90
Diabetes (With risk factors)	< 70	< 100	< 70
Subclinical Atherosclerosis (CAC ≥ 1000)	< 55	< 85	< 55
Clinical ASCVD (Very High Risk) or CKD	< 55	< 85	< 55

Source: 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.

On ApoB: The guideline recommends ApoB to guide therapy in patients with diabetes, cardiovascular-kidney-metabolic (CKM) syndrome, or elevated triglycerides. In these patients, LDL-C can meaningfully underestimate atherogenic particle burden — so ApoB gives a more accurate picture of actual risk. This is the discordance that matters clinically. A patient with diabetes, a triglyceride of 210, and an LDL of 95 may look like she's at goal while her ApoB tells a different story.

I order ApoB routinely in metabolically complex patients. The guideline now backs that up.

Pharmacological Options: Statins and Beyond

Statins remain the backbone of lipid-lowering therapy. The intensity levels haven't changed:

Intensity	Drug and Dose	Expected LDL-C Reduction
High	Atorvastatin 40–80 mg; Rosuvastatin 20–40 mg	≥ 50%
Moderate	Atorvastatin 10–20 mg; Rosuvastatin 5–10 mg; Simvastatin 20–40 mg	30–49%
Low	Simvastatin 10 mg; Pravastatin 10–20 mg; Lovastatin 20 mg	< 30%

Source: 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.

When statins alone are not enough, the add-on options are:

• Ezetimibe: ~25% additional LDL reduction, Class I recommendation when added to a statin

• PCSK9 inhibitors (alirocumab, evolocumab): 45–64% reduction — the most powerful available for patients who can't reach goal on statin + ezetimibe

• Inclisiran: 48–52% reduction via a twice-yearly injection — an option for patients with adherence barriers to daily oral medications

• Bempedoic acid: 17–24% reduction, useful for true statin intolerance

One drug interaction worth knowing: gemfibrozil is absolutely contraindicated with any statin. This is not new, but it remains under-recognized.

Hypertriglyceridemia: The Overlooked Piece

The 2026 guideline gives significant attention to triglyceride management, including specific lifestyle targets as TG levels rise.

Intervention	TG 150–499 mg/dL	TG 500–999 mg/dL	TG ≥ 1000 mg/dL
Added Sugars	< 6% of calories	< 5% of calories	Eliminate
Total Fat	30–35% of calories	20–25% of calories	10–15% of calories
Alcohol	Avoid	Abstain completely	Abstain completely
Physical Activity	≥ 150 min/week	≥ 150 min/week	≥ 150 min/week
Weight Loss	5–10% goal	5–10% goal	5–10% goal

Source: 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. Note: TG ≥ 1000 mg/dL requires mandatory referral to a registered dietitian (Class I recommendation).

Severely elevated triglycerides (above 1000 mg/dL) carry pancreatitis risk and require a referral to a registered dietitian — that's a Class I recommendation in the guideline, not optional.

A note on omega-3 supplements: the guideline does not recommend over-the-counter fish oil for general heart health — that's Class III, meaning no benefit and potential harm at high doses.

Prescription omega-3s like icosapentaenoic acid (Vascepa) have specific indications in patients with persistently elevated triglycerides (above 150 mg/dL) who are already on a statin.

If you're taking fish oil because someone told you it's good for your heart, that conversation deserves a second look.

What This Means for How I Practice

I opened Well Endocrinology in 2023 with a specific clinical philosophy: order Lp(a) on every new patient, use ApoB in metabolically complex cases, and factor CAC scoring into risk decisions where there's uncertainty. That's not because I was ahead of my time. It's because the data supporting all three of those practices predates the 2026 guideline by years.

The guideline formalizes what the evidence already showed.

What it also formalizes: cardiovascular risk is a metabolic story, not just a cholesterol story. If you have diabetes, PCOS, thyroid disease, or significant weight-related metabolic changes, your lipid picture looks different and deserves to be read differently. The LDL-ApoB discordance is most pronounced in exactly those patients.

This is where endocrinology and cardiology overlap — and where a practice focused on metabolic health can do work that a general lipid check at your annual physical cannot.

When to Ask for a More Thorough Evaluation

The 2026 guideline identifies specific situations that warrant referral to a lipid specialist. They include:

• Confirmed or suspected familial hypercholesterolemia (LDL ≥ 190 mg/dL)

• Premature ASCVD before age 40

• Inability to achieve ≥ 50% LDL reduction on combination therapy

• Statin side effects across two or more different statins

• Lp(a) ≥ 200 nmol/L or ≥ 75 mg/dL

• Severe primary hypertriglyceridemia

More broadly: if you have a strong family history of early heart disease, if your labs look "fine" but something doesn't add up, or if you've been told your cholesterol is managed but nobody has ever checked Lp(a) or ApoB — that's worth a closer look.

If you'd like to go through your lipid picture with that kind of thoroughness, I'm happy to schedule a time to talk.

Reference: Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.